[ad_1]
![](https://i0.wp.com/www.scottins.com/wp-content/uploads/2020/12/COVIDTESTKIT.jpg?resize=800%2C400&ssl=1)
On November 17, 2020, the FDA issued emergency use authorization (EUA) for the primary self-test package for COVID-19 that may present fast outcomes at residence with 94%-98% accuracy.
Whereas Lucira’s single-use take a look at is at the moment solely accessible at Sutter Well being in Northern California and the Cleveland Clinic in South Florida, it’s anticipated to be accessible nationwide in early 2021. The take a look at package – estimated to value round $50 – would require a prescription and all outcomes have to be reported to well being authorities. People over the age of 14 who’re displaying signs of COVID-19 will be capable to self-administer the take a look at and get outcomes at residence inside half-hour. The take a look at can also be licensed to be used in physician’s workplaces, hospitals, pressing care facilities and emergency departments for sufferers of all ages.
Will this take a look at be the reply to making sure the protection of staff returning to work?
There isn’t any doubt that this EUA-approved take a look at is a vital development to deal with the continued pandemic and might be a useful instrument to get life again to extra normalcy. However, as with all take a look at, it shouldn’t be seen as the only gatekeeper to figuring out if staff can come to work. This newly-approved fast take a look at, like all COVID-19 assessments, supplies outcomes at a single cut-off date. To make sure ongoing unfavorable outcomes, the take a look at would require common, if not each day, repeating. As a single-use take a look at package, the price alone perhaps be a deterrent for employers.
Absent a dramatic change within the availability and price of fast assessments, the solutions to making sure staff are protected at work are the identical as they’ve been for months: Put on a Masks – Wash Your Arms – Preserve Social Distancing.
[ad_2]